SYNE1 mutation may enhance the response to immune checkpoint blockade therapy in clear cell renal cell carcinoma patients

As one of the 10 most common cancers in men, the incidence of renal cell carcinoma (RCC) has been increasing in recent years. Clear cell renal cell carcinoma (ccRCC) is the most common pathological type of RCC, counting for 80%-90% of cases. Immunotherapy is becoming increasingly important in the tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Pengju, Xiao, Jeifei, Zhou, Bangfen, Wei, Jinhuan, Luo, Junhang, Chen, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732295/
https://www.ncbi.nlm.nih.gov/pubmed/33031058
http://dx.doi.org/10.18632/aging.103781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732295/
https://www.ncbi.nlm.nih.gov/pubmed/33031058
http://dx.doi.org/10.18632/aging.103781

Ejemplares similares